πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 454 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11028161

Treating refractory migraine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11028160

Treating refractory migraine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10981986

Fusions of antibodies to CD38 and attenuated interferon alpha

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10899826

Pharmaceutical compositions for an anti-CGRP antagonist antibody

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10835503

Pre-filled syringe

Teva Pharmaceuticals USA, Inc. Β· Granted Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10822422

Antibodies against TL1a and uses thereof

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD Β· Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10689352

Solid state forms of trisodium valsartan: sacubitril

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10676498

Processes for the preparation of sofosbuvir and intermediates thereof

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10653704

Inhalable formulation

Teva Branded Pharmaceutical Products R&D, Inc. Β· Granted Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10646443

Sustained release olanzapine formulations

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10640487

Solid state forms of Nilotinib salts

Teva Pharmaceuticals USA, Inc. Β· Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10604537

Solid state forms of ixazomib citrate

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Mar 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10597448

Methods for treating visceral pain associated with interstitial cystitis by administering

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10556945

Antagonist antibodies directed against calcitonin gene-related peptide and methods using s

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10544199

Interferon alpha 2B variants

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD Β· Granted Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10519224

Treating headache comprising administering an antibody to calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10392434

Treating refractory migraine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10342867

Adjuvants

LITEVAX B.V. Β· Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10329343

Methods for treating headache using antagonist antibodies directed against calcitonin gene

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10323085

Methods of treating fibromyalgia

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10314819

Solid state forms of Eluxadoline

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10232041

Combination of lenalidomide and polypeptide construct, and uses thereof

TEVA PHARMACEUTICALS PTY LTD Β· Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10214553

Solid state forms of sofosbuvir

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10188811

Nasal spray device

Teva Branded Pharmaceutical Products R&D, Inc. Β· Granted Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted